SSSW(SH:688399) 2 1 Shi Ji Jing Ji Bao Dao·2025-08-28 08:52Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), announced that several executives voluntarily proposed salary reductions in response to ongoing industry challenges and to support long-term development [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman and general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2]. - Other executives, including Liu Zhonghua (40% reduction), Hu Yuanyuan (40% reduction), and Zhou Guohui (40% reduction), will also see significant salary cuts, while the financial director and employee supervisors will have reductions of 10% and 5% respectively [2][3]. Executive Compensation Context - Among the seven executives who proposed salary cuts, five had annual salaries exceeding 1 million yuan in 2024, with Fang Yongsheng earning 2.0643 million yuan and Wang Guoqiang earning 2.4399 million yuan [3][4]. - The company previously had several executives with annual salaries exceeding 10 million yuan in 2021 and 2022 [4]. Financial Performance - The company has faced continuous operational pressure, with a reported revenue of 176 million yuan in the first half of 2025, a year-on-year decrease of 1.05%, and a net profit of 3.9926 million yuan, down 86.35% [7]. - Shuoshi Biotechnology has recorded net losses for two consecutive years, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively [7]. Dividend Distribution - Despite the decline in performance and executive salary reductions, the company plans to distribute a cash dividend of 2.85 billion yuan for the first half of 2025, reflecting a commitment to return value to shareholders [9]. - The company reported that as of June 30, the undistributed profits exceeded 2.4 billion yuan, allowing for the dividend distribution while maintaining a stable cash flow [9].